FINANCIAL STATEMENTS Notes to the Consolidated Financial Statements Continued 20.
Collateralised and restricted cash As at 31 December Collateralised and restricted cash amounted to $40 million, mainly represent restricted cash held in an escrow account $38 million related 2015 2014 to the acquisition of EIMC United Pharmaceuticals note 44, in addition to restricted cash retained against short-term bank transactions $m $m granted to the Groups Sudanese, Algerian, Jordanian and US operations.
2014: Sudanese, Egyptian, Algerian, Jordanian, and US Trade receivables 432 384 operations of $8 million.
Prepayments 39 42 VAT and sales tax recoverable 15 12 22.
Cash and cash equivalents Employee advances 2 1 As at 31 December 488 439 2015 2014 $m $m Trade receivables are stated net of provisions for chargebacks and doubtful debts as follows: Cash at banks and on hand 102 81 As at As at Time deposits 429 183 31 December Translation 31 December Money market deposits 22 16 2014 Additions Utilisation adjustments 2015 $m $m $m $m $m 553 280 Chargebacks and other allowances 85 524 524 85 Cash and cash equivalents include highly liquid investments with maturities of three months or less.
Other current assets The following table provides a summary of the age of trade receivables: Other current assets mainly represents the agreement the Group entered with an asset management firm to manage a $20 million equity Past due portfolio.
This investment is measured at fair value and any changes in fair value go through other comprehensive income.
Not past The fair value of financial assets and liabilities is included at the amount at which the instrument could be exchanged in a current transaction due on the between between reporting less than 91 and 180 181 and 360 Over one between willing parties, other than in a forced or liquidation sale.
Management classifies items that are recognised at fair value based on the date 90 days days days year Impaired Total level of inputs used in their fair value determination.
At 31 December 2015 $m $m $m $m $m $m $m Total trade receivables as at This asset is classified as level 1 quoted prices in active markets.
Bank overdrafts and loans 423 50 25 15 4 517 As at 31 December Chargebacks and other allowances 85 2015 2014 Net receivables 432 $m $m Bank overdrafts 8 19 Past due Import and export financing 58 83 Not past due on the between between Short-term loans 4 227 reporting less than 91 and 180 181 and 360 Over Current portion of long-term loans note 28 45 64 date 90 days days days one year Impaired Total 115 393 At 31 December 2014 $m $m $m $m $m $m $m Total trade receivables as at 2015 2014 31 December 2014 334 60 26 22 27 35 504 % % Related allowance for doubtful debts 35 35 The weighted average interest rates paid were as follows: 334 60 26 22 27 469 Bank overdrafts 6.19 5.50 Chargebacks and other allowances 85 Bank loans including the non-current bank loans 2.77 2.50 Net receivables 384 Eurobond 4.25 Import and export financing 3.09 3.34 The Group establishes an allowance for impairment that represents its estimate of losses in respect of specific trade and other receivables, where it is deemed that a receivable may not be recoverable.
When the receivable is deemed irrecoverable, the allowance account is writtenImport and export financing represents short-term financing for the ordinary trading activities of the business.
off against the underlying receivable.
2014: Short-term loans mainly represent a one year syndicated bridge loan of $225 million which was entered into on 7 July 2014.
More details on the Groups policy for credit and concentration of risk management are provided in Note 30.
The bridge loan has been used to finance the acquisition of Bedford Laboratories and was fully repaid during year 2015.
